Eubel Brady & Suttman Asset Management Inc Gilead Sciences, Inc. Transaction History

Eubel Brady & Suttman Asset Management Inc

$691 Million
Q2 2024

2 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q3 2021 Nov 05, 2021	SELL	$67.69 - $73.03 $16,922 - $18,257	-250 Closed	0 $0
Q2 2021 Aug 17, 2021	BUY	$63.47 - $69.35 $15,867 - $17,337	250 New	250 $16,000

Others Institutions Holding GILD

# of Institutions

1,893

Shares Held

1.02B

Call Options Held

12M

Put Options Held

9.04M

Black Rock Inc. New York, NY

121M
Shares

$10.6 Billion
0.19% of portfolio
Vanguard Group Inc Valley Forge, PA

115M
Shares

$10.2 Billion
0.15% of portfolio
Capital World Investors Los Angeles, CA

76.2M
Shares

$6.72 Billion
0.88% of portfolio
Capital Research Global Investors Los Angeles, CA

60.4M
Shares

$5.32 Billion
0.94% of portfolio
State Street Corp Boston, MA

59.3M
Shares

$5.23 Billion
0.18% of portfolio

View Full List

About GILEAD SCIENCES, INC.

Ticker GILD
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,253,369,984
Market Cap $110B
Description
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...

More about GILD

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Eubel Brady & Suttman Asset Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Eubel Brady & Suttman Asset Management Inc with notifications on news.

Account